PMCB (PharmaCyte Biotech) Insider Ownership: 11.97 % (As of Aug. 11, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PMCB PharmaCyte Biotech Inc PMCB
34 GF Score
Price $0.54
! 2 Warning Signs
View Full Analysis

What is PharmaCyte Biotech Insider Ownership?

PharmaCyte Biotech PMCB -0.66% 34 Insider Ownership is 11.97 % as of Aug. 11, 2026. GuruFocus rates PMCB with a GF Score™ of 34/100. The stock has 2 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, PharmaCyte Biotech's insider ownership is 11.97%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, PharmaCyte Biotech's Institutional Ownership is 9.11%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, PharmaCyte Biotech's Float Percentage Of Total Shares Outstanding is 94.42%.

PharmaCyte Biotech Insider Ownership Historical Data

* Premium members only.

The historical data trend for PharmaCyte Biotech's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmaCyte Biotech Insider Ownership Chart

PharmaCyte Biotech Historical Data

The historical data trend for PharmaCyte Biotech can be seen below:

2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30 2026-01-31 2026-02-28 2026-05-31 2026-06-30 2026-07-31
Insider Ownership 9.38 9.48 9.48 9.48 9.48 12.68 12.68 11.97 11.97 11.97
PMCB
34GF Score
PharmaCyte Biotech Inc PMCB
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PharmaCyte Biotech Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 11.97 % mean?
PharmaCyte Biotech (PMCB) has a Insider Ownership of 11.97 % as of Aug. 11, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on PharmaCyte Biotech and its competitors.
Is PharmaCyte Biotech's Insider Ownership too high?
PharmaCyte Biotech's current Insider Ownership is 11.97 %. Overall, PharmaCyte Biotech has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does PharmaCyte Biotech's Insider Ownership compare to NIKI and IMNN?
PharmaCyte Biotech's Insider Ownership of 11.97 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on PharmaCyte Biotech and its competitors. PharmaCyte Biotech's current Insider Ownership is 11.97 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCyte Biotech stock overvalued right now?
PharmaCyte Biotech (PMCB) has a current Insider Ownership of 11.97 %. The current Insider Ownership is 11.97 %. PharmaCyte Biotech's overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For PharmaCyte Biotech (PMCB), the current Insider Ownership is 11.97 % as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PharmaCyte Biotech Business Description

Address 3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV, USA, 89169
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
34GF Score

Get the complete analysis for PMCB

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.54
Price